Sustained-Release Niacin with niaXtend 500 mg
Product analysis
Sustained-Release Niacin with niaXtend 500 mg provides nicotinic acid, a niacin form that can affect blood fats. Those changes do not establish better protection from heart problems, and the release format does not show an extra heart benefit.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality100
Nicotinic acid is clearly identified, helping distinguish it from other niacin forms. That clarity does not by itself establish a special benefit from sustained release.
Ingredient Transparency100
The niacin amount and exact form are clearly stated. That allows a direct comparison with other nicotinic acid preparations.
Value For Money60
Niacin offers moderate value at the serving cost. A sustained-release name alone does not establish an additional value advantage.
Customer Satisfaction81
Customer feedback is generally favorable. A substantial number of ratings supports that impression, without proving effectiveness or safety.
Product Focus68
A single active ingredient keeps the formula focused on blood-fat-related goals. Changes in blood fats do not reliably show a reduction in major heart-related outcomes.
- Format
Tablet - Container
- 120 Tablet(s)
- Per serving
- $0.14
- Customer rating
- 4.7 · 1,086 ratings
Goals
Nicotinic acid can change lipid markers, which explains the saved triglyceride contribution. Its 500 mg per serving reaches the configured amount criterion, but that criterion is not a proven dose for preventing cardiovascular events. A major trial of extended-release niacin with laropiprant added to statins did not improve major vascular outcomes; this specific result does not establish every niacin product ineffective.
How this product is rated for Cardiovascular Support
Ingredient fit96
Goal fit
Dose adequacy
Pathways53
Depth
Breadth
Evidence74
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Nicotinic acid at 500 mg relates to blood-lipid metabolism. Lipid changes have not reliably translated into additional cardiovascular event reduction, and the sustained-release format should not be treated as evidence of superior heart protection.
How this product is rated for Heart Health
Ingredient fit96
Goal fit
Dose adequacy
Pathways18
Depth
Breadth
Evidence62
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Niacin (Nicotinic Acid) | 500 mg |
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
- Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
- Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
- Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
- Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
- Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.